City of Hope Comprehensive Cancer Center

Beckman Research Institute

Duarte, CA

Sorting 32 by

Accepting patients

REM-422

A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS
Learn more
  • MYB mRNA Degrader
  • Phase 1

Accepting patients

ACCESS

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)
Learn more
  • Allogeneic Stem Cell Transplant
  • Pre-Transplant
  • Phase 2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

OPTIMIZE

A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

GLB-001

A First-in-human, Phase 1, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Learn more
  • Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor)
  • High Risk
  • Phase 1

Accepting patients

BTX-A51

A First-In-Human, Open-Label, Escalating Multiple-Dose Study to Evaluate the Safety, Toxicity, and Pharmacokinetics of BTX-A51 Capsules Alone and in Combination With Azacitidine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Learn more
  • CK1-Alpha Inhibitor
  • Phase 1
  • Has results

Not yet accepting

S227928

Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination With Venetoclax in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)
Learn more
  • Antibody Drug Conjugate (ADC)
  • MCL-1 Inhibitor
  • CD74
  • Phase 1/2

Accepting patients

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 1

Accepting patients

BEXMAB

A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination With Standard of Care Therapy in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia
Learn more
  • BCL-2 Inhibitor
  • Monoclonal Antibody
  • Clever-1
  • Phase 1/2
  • Has results

Accepting patients

KER-050

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Learn more
  • Growth Factor
  • Phase 2
  • Has results

Not currently accepting

A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects With Leukemias or Myelodysplastic Syndrome (MDS)
Learn more
  • Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor)
  • Phase 1/2